Pular para o conteúdo
Síndrome antifosfolipídico
ORPHA:80CID-10 · D68.6CID-11 · 4A45DOENÇA RARA
Visão / ocular
Também conhecida comoAPLSAVC
Sinônimos clínicos: Síndrome do anticorpo anti-fosfolípido · APLS clássico · APLS · +1

É uma condição causada por autoanticorpos, que são defesas do corpo que, por engano, atacam a si mesmas. Esses autoanticorpos agem contra os fosfolipídios (certas gorduras presentes nas células), o que faz o sangue coagular mais do que deveria. Isso pode levar à formação de coágulos, derrame (AVC), infarto e, em mulheres, a problemas sérios na gravidez, como aborto espontâneo e perda do bebê antes ou durante o parto (natimorto). Essa síndrome costuma estar ligada a outras doenças autoimunes, sendo a mais comum o lúpus, e também a infecções, como sífilis e doença de Lyme.

Em construçãohistóricoSugerir correção
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

💬
EM LINGUAGEM SIMPLES

A síndrome do anticorpo antifosfolípido é um distúrbio caracterizado por uma tendência aumentada de formar coágulos sanguíneos anormais (tromboses) que podem bloquear os vasos sanguíneos. Essa tendência de coagulação é conhecida como trombofilia. Na síndrome do anticorpo antifosfolípido, as tromboses podem se desenvolver em quase qualquer vaso sanguíneo do corpo. Se um coágulo sanguíneo se forma nos vasos do cérebro, o fluxo sanguíneo é prejudicado e pode levar a AVC. A síndrome do anticorpo antifosfolípido é um distúrbio autoimune. Distúrbios autoimunes ocorrem quando o sistema imunológico ataca os próprios tecidos e órgãos do corpo.

Mulheres com síndrome do anticorpo antifosfolípido têm risco aumentado de complicações durante a gravidez. Essas complicações incluem pressão alta induzida pela gravidez (preeclâmpsia), placenta subdesenvolvida (insuficiência placentária), parto prematuro ou perda da gravidez (aborto espontâneo). Além disso, mulheres com síndrome do anticorpo antifosfolípido têm risco maior de ter uma trombose durante a gravidez do que em outros momentos de suas vidas. No nascimento, bebês de mães com síndrome do anticorpo antifosfolípido podem ser pequenos e com baixo peso.

Uma trombose ou complicação da gravidez costuma ser o primeiro sinal da síndrome do anticorpo antifosfolípido. Essa condição geralmente aparece no início ou meio da idade adulta, mas pode surgir em qualquer idade.

Outros sinais e sintomas da síndrome do anticorpo antifosfolípido que afetam as células sanguíneas e os vasos incluem uma quantidade reduzida de células envolvidas na coagulação sanguínea chamadas plaquetas (trombocitopenia), escassez de glóbulos vermelhos (anemia) devido à sua destruição prematura (hemólise), e uma descoloração roxa da pele (livedo reticular) causada por anomalias nos pequenos vasos sanguíneos da pele. Além disso, as pessoas com a condição podem apresentar feridas abertas (úlceras) na pele, dores de cabeça tipo enxaqueca ou doença cardíaca. Muitas pessoas com síndrome do anticorpo antifosfolípido também têm outros distúrbios autoimunes, como lúpus eritematoso sistêmico.

Raramente, pessoas com síndrome do anticorpo antifosfolípido desenvolvem tromboses em múltiplos vasos sanguíneos por todo o corpo. Essas tromboses bloqueiam o fluxo sanguíneo nos órgãos afetados, o que prejudica sua função e, em última instância, causa insuficiência orgânica. Essas pessoas são consideradas como tendo síndrome antiphosfolípida catastrófica (CAPS). A CAPS tipicamente afeta os rins, pulmões, cérebro, coração e fígado, e é fatal em mais da metade das pessoas afetadas. Menos de 1 por cento das pessoas com síndrome do anticorpo antifosfolípido desenvolvem CAPS.

Fonte: MedlinePlus Genetics (NLM/NIH), traduzido
📋
Informacoes curadas por IA — podem conter imprecisoes

É uma condição causada por autoanticorpos, que são defesas do corpo que, por engano, atacam a si mesmas. Esses autoanticorpos agem contra os fosfolipídios (certas gorduras presentes nas células), o que faz o sangue coagular mais do que deveria. Isso pode levar à formação de coágulos, derrame (AVC), infarto e, em mulheres, a problemas sérios na gravidez, como aborto espontâneo e perda do bebê antes ou durante o parto (natimorto). Essa síndrome costuma estar ligada a outras doenças autoimunes, sendo a mais comum o lúpus, e também a infecções, como sífilis e doença de Lyme.

Pesquisas ativas
51 ensaios
123 total registrados no ClinicalTrials.gov
Publicações científicas
10.591 artigos
Último publicado: 2026 Apr 17
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: D68.6
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

❤️
Coração
12 sintomas
🩸
Sangue
10 sintomas
👁️
Olhos
5 sintomas
🧠
Neurológico
4 sintomas
🫁
Pulmão
2 sintomas
🫘
Rins
2 sintomas

+ 40 sintomas em outras categorias

Características mais comuns

90%prev.
Retardo do crescimento intrauterino
Muito frequente (99-80%)
55%prev.
Trombose arterial
Frequente (79-30%)
55%prev.
Positividade para anticorpo anti-beta 2 glicoproteína I
Frequente (79-30%)
55%prev.
Hipertensão
Frequente (79-30%)
55%prev.
Positividade do anticorpo IgG anticardiolipina
Frequente (79-30%)
55%prev.
Positividade do anticorpo antifosfolipídeo
Frequente (79-30%)
80sintomas
Muito frequente (1)
Frequente (20)
Ocasional (17)
Muito raro (1)
Sem dados (41)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 80 características clínicas mais associadas, ordenadas por frequência.

Retardo do crescimento intrauterinoIntrauterine growth retardation
Muito frequente (99-80%)90%
Trombose arterialArterial thrombosis
Frequente (79-30%)55%
Positividade para anticorpo anti-beta 2 glicoproteína IAnti-beta 2 glycoprotein I antibody positivity
Frequente (79-30%)55%
HipertensãoHypertension
Frequente (79-30%)55%
Positividade do anticorpo IgG anticardiolipinaAnticardiolipin IgG antibody positivity
Frequente (79-30%)55%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico10.591PubMed
Últimos 10 anos200publicações
Pico2026145 papers
Linha do tempo
2026Hoje · 2026🧪 1997Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

🧬

Nenhum gene associado encontrado

Os dados genéticos desta condição ainda estão sendo catalogados.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
✓Aprovado7
3Fase 32
2Fase 215
1Fase 112
·Pré-clínico64
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 100 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Síndrome antifosfolipídico

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Onde estão os ensaios

Com ensaio aberto em 25 países. O ponto verde marca onde há vaga agora.

🟢 Recrutando agora

39 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

NCT07087912 · Safety and Immunogenicity of the Live Attenuated Tetravalent…Recrutando
PHASE4🇧🇷 Brasil
NCT07757789 · Thrombocytopenia Trajectories in Antiphospholipid Syndrome: …Recrutando
NA🇪🇬 Egito
NCT07743242 · Autoimmune Hemolytic Anemia and Its Clinical Implication on …Recrutando
NA🇪🇬 Egito
NCT07584083 · Anifrolumab in Adults With Primary Antiphospholipid Syndrome…Recrutando
PHASE2Greece
NCT07251179 · Characterization of Autoreactive b Lymphocytes in Autoimmune…Recrutando
🇫🇷 França
NCT07301164 · Clinical Study of BCT301 Cell Injection Therapy for Refracto…Recrutando
EARLY_PHASE1🇨🇳 China
NCT07372170 · Observational Study to Evaluate the Effectiveness of DOACS f…Recrutando
🇪🇸 Espanha
NCT07142239 · Hematological Markers MPV, PLR, and NLR in Primary Versus Se…Recrutando
🇪🇬 Egito
NCT07236762 · An Exploratory Clinical Study of YTS109 Cell for R/R Autoimm…Recrutando
PHASE1🇨🇳 China
NCT07236801 · Exploratory Clinical Study on YTS109 Cell Therapy for Autoim…Recrutando
PHASE1🇨🇳 China
NCT07163338 · Prevalence and Consequences of Antiphospholipid Syndrome in …Recrutando
NA🇫🇷 França
NCT07123519 · A Clinical Study of YTS109 Cells for the Treatment of R/R Au…Recrutando
PHASE1🇨🇳 China
NCT07104721 · A Clinical Study of YTS109 Cell for R/R Autoimmune DiseasesRecrutando
PHASE1🇨🇳 China
NCT06828042 · Safety and Efficacy of Universal CD19-targeting CAR-γδT Cell…Recrutando
PHASE1, PHASE2🇨🇳 China
NCT06978647 · A Clinical Study of YTS109 Cell in R/R Autoimmune DiseasesRecrutando
PHASE1🇨🇳 China
NCT06373926 · Evaluation of Cell Membrane Expression of Annexin A2 on Mono…Recrutando
NA🇫🇷 França
NCT06614270 · Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Aut…Recrutando
NA🇨🇳 China
NCT06794008 · BCMA-CD19 CAR-T Therapy for Refractory Autoimmune DiseasesRecrutando
PHASE2🇨🇳 China
NCT06373003 · Negative Antiphospholipid Syndrome: a Multicentric StudyRecrutando
🇮🇹 Itália
NCT07085676 · Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmu…Recrutando
PHASE1🇮🇱 Israel
NCT06371417 · Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW …Recrutando
PHASE1🇦🇺 Austrália · 🇦🇹 Áustria · Bulgaria +17
NCT06747312 · Effect of Belimumab on Antibody Titers in Primary APS Patien…Recrutando
PHASE2🇨🇳 China
NCT05904301 · Armenian NAtionwide REGistry of Systemic Autoimmune and Auto…Recrutando
Armenia
NCT05671757 · Daratumumab in Primary Antiphospholipid SyndromeRecrutando
PHASE1, PHASE2🇺🇸 Estados Unidos
NCT05679206 · Antiphospholipid Syndrome and Postpartum Pulmonary Artery Pr…Recrutando
🇨🇭 Suíça
NCT05786235 · Patients Pregnant Women With or Without Primary Antiphosphol…Recrutando
🇮🇹 Itália
NCT05230017 · Chinese AntiphosPholipid Syndrome cohorT cOllaborative NEtwo…Recrutando
🇨🇳 China
NCT05646394 · Registry on Augmented Antithrombotic Treatment Regimens for …Recrutando
🇦🇷 Argentina · 🇨🇦 Canadá
NCT05199909 · Safety and Efficacy of Zanubrutinib in the Treatment of Anti…Recrutando
PHASE2🇨🇳 China
NCT04308564 · Laboratory and Clinical Data in Antiphospholipid PatientsRecrutando
🇫🇷 França
NCT04262492 · International Registry of Thrombotic APS Patients Treated Wi…Recrutando
🇫🇷 França
NCT07178925 · Follow-up Cohort of Patients With Antiphospholipid SyndromeRecrutando
🇫🇷 França
NCT03152058 · IMPACT Study: IMProve Pregnancy in APS With Certolizumab The…Recrutando
PHASE2🇨🇦 Canadá · 🇺🇸 Estados Unidos
NCT00616317 · Register for Pediatric Patients With Antiphospholipid Syndro…Recrutando
🇺🇸 Estados Unidos
NCT00482794 · Genetic Risk Factors Associated With Antiphospholipid Antibo…Recrutando
🇺🇸 Estados Unidos
NCT00198068 · Predictors of Pregnancy Outcome in Systemic Lupus Erythemato…Recrutando
🇨🇦 Canadá · 🇬🇧 Reino Unido · 🇺🇸 Estados Unidos
NCT06723106 · Phase 1b Long-term Extension Trial of RAY121 in Immunologica…Por convite
PHASE1🇦🇺 Austrália · 🇦🇹 Áustria · Bulgaria +16
NCT05859997 · Universal CAR-T Cells (BRL-301) in Relapse or Refractory Aut…Por convite
NA🇨🇳 China
NCT05583305 · Prevalence and Etiologies of Intracranial Stenosis in Patien…Por convite
Hong Kong

Outros ensaios clínicos

123 ensaios clínicos encontrados, 51 ativos.

Distribuição por fase
NCT07737470 · Inflammatory Disease Biobank for Immunophenotyping and Cardi…Em breve
NCT07570511 · Point of Care Testing INR in Antiphospholipid SyndromeEm breve
NA🇫🇷 França
NCT07439029 · YTS109 in Pediatric Relapsed/Refractory Autoimmune DiseasesEm breve
PHASE1🇨🇳 China
NCT07212322 · A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Dis…Em breve
NA🇨🇳 China
NCT06884384 · DOAC Versus VKA in Patients With Non-high-risk APS : Prospec…Em breve
🇫🇷 França
NCT07108023 · Hematological Disorders in EHPVO PatientsEm breve
NCT06929182 · OBServaToIre interNational Des Patients AnTiphospholipidEs t…Em breve
🇪🇸 Espanha
NCT06808607 · Clinical Outcomes of Primary Versus Secondary Antiphospholip…Em breve
🇪🇬 Egito
NCT06504420 · The Safety and Efficiency of Sirolimus in Primary Antiphosph…Em breve
PHASE2
NCT06420154 · The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients…Em breve
EARLY_PHASE1🇨🇳 China
NCT07632976 · A Phase I, Dose Escalation, Open-label, Multicenter Study of…Ativo
PHASE1🇨🇳 China
NCT05995600 · Comparison of Clopidogrel-based Antiplatelet Therapy Versus …Ativo
PHASE4South Korea
NCT06133621 · Determination of Reference Values for Diluted Russell's Vipe…Concluído
🇫🇷 França
NCT06315530 · Effect of Telitacicept on Antibody Titers in Primary APS Pat…Concluído
PHASE2🇨🇳 China
NCT05416190 · Effect of Injectable Anticoagulants on Research for a Circul…Concluído
NA🇫🇷 França
NCT05313048 · Prospective Observational Study to Evaluate a Possible Chang…Concluído
🇩🇪 Alemanha
NCT03684564 · RIvaroxaban for Stroke Patients With AntiPhospholipid Syndro…Concluído
PHASE2🇬🇧 Reino Unido
NCT04319341 · Obstetric Antiphospholipid Antibody Syndrome : Contribution …Concluído
🇫🇷 França
NCT03994302 · Monitoring the Antiphospholipid Syndrome:TOXicity of Drugs (…Concluído
🇫🇷 França
NCT03890601 · New Biological Tests in Patients With Antiphospholipid Antib…Concluído
🇫🇷 França
NCT03893357 · Prevalence of Antiphospholipid Antibodies in the Hemodialysi…Concluído
🇧🇪 Bélgica
NCT03600636 · Medium-term Follow-up of Patients With Obstetric Antiphospho…Concluído
NA🇫🇷 França
NCT03682419 · Evaluation of Precision and Accuracy of INR Measurements in …Concluído
🇬🇧 Reino Unido
NCT03348306 · Multi-organ Screening for Asymptomatic Ischaemia in Antiphos…Concluído
NA🇫🇷 França
NCT03969498 · Evaluation of the Incidence of Cancer in the Follow-up of Wo…Concluído
🇫🇷 França
NCT03459508 · Ocular Findings in Women With Primary Antiphospholipid Syndr…Concluído
🇪🇬 Egito
NCT02782039 · Register of Patients With Anti-Phospholipids Syndrome (APS) …Concluído
🇫🇷 França
NCT02466217 · Phenomics in Autoimmune and Inflammatory DiseasesConcluído
🇫🇷 França
NCT02139072 · CoaguChek XS in Antiphospholipid Antibody Syndrome (APL) Pat…Concluído
🇺🇸 Estados Unidos
NCT05195372 · Effectivity and Safety of Different Anticoagulants in Patien…Concluído
🇩🇪 Alemanha
NCT02295475 · Apixaban for Secondary Prevention of Thromboembolism Among P…Concluído
PHASE4🇺🇸 Estados Unidos
NCT02326051 · Timing of Initiation of LMWH Administration in Pregnant Wome…Concluído
PHASE4🇪🇬 Egito
NCT02116036 · Rivaroxaban for Antiphospholipid Antibody SyndromeConcluído
PHASE4🇨🇦 Canadá
NCT02926170 · Rivaroxaban for Patients With Antiphospholipid SyndromeConcluído
PHASE3🇪🇸 Espanha
NCT01787305 · Pilot Study of Gut Commensals in Antiphospholipid SyndromeConcluído
🇺🇸 Estados Unidos
NCT04153201 · Hydroxychloroquine for Thrombosis Prevention and Antiphospho…Concluído
NAGreece
NCT01660061 · Monitoring Anticoagulant Therapy in Antiphospholipid Syndrom…Concluído
🇩🇪 Alemanha
NCT01318057 · Pharmacogenetics of Warfarin in Puerto Ricans.Concluído
Puerto Rico
NCT01475149 · Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid …Concluído
🇺🇸 Estados Unidos
NCT01029587 · Eculizumab to Enable Renal Transplantation in Patients With …Concluído
PHASE2🇺🇸 Estados Unidos
NCT00878137 · Reliability of Point-of-care INR Measurements in Patients Wi…Concluído
🇺🇸 Estados Unidos
NCT00674297 · Effects of Fluvastatin on Proinflammatory and Prothrombotic …Concluído
PHASE2🇺🇸 Estados Unidos
NCT00537290 · A Pilot Study of Rituximab for the Anticoagulation Resistant…Concluído
PHASE2🇺🇸 Estados Unidos
NCT01104337 · Drug Interaction Between Paracetamol and WarfarinConcluído
PHASE4🇫🇷 França
NCT01051778 · Low-molecular-weight Heparin (LMWH) Versus Unfractionated He…Concluído
PHASE2🇪🇬 Egito
NCT02892565 · Hypercoagulable Phenotype by Thrombinography (in Presence of…Concluído
NA
NCT02833194 · Assessment of the Prevalence of Major Psychiatric Disorders …Concluído
🇫🇷 França
NCT02855047 · The Prognostic Value of PGF and sFlt1 Variations Induced by …Concluído
🇫🇷 França
NCT01762891 · CI(R)CA : Coumadin Interaction With Rofecoxib, Celecoxib and…Concluído
NA
NCT00076713 · Antiphospholipid Syndrome Collaborative Registry (APSCORE)Concluído
🇺🇸 Estados Unidos
NCT00180817 · Longitudinal Study of the Clinical and Haematological Cause …Concluído
🇬🇧 Reino Unido
NCT00010400 · Pilot Study of Cyclophosphamide in Patients With Life-Threat…Concluído
NA🇺🇸 Estados Unidos
NCT01956188 · Omega 3 in LES and APSUNKNOWN
NA🇧🇷 Brasil
NCT01151644 · Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rhe…UNKNOWN
PHASE4🇧🇷 Brasil
NCT06379646 · An Clinical Study of YTS109 Cell Injection in Subjects With …UNKNOWN
NA🇨🇳 China
NCT06373081 · Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune…UNKNOWN
NA🇨🇳 China
NCT05983952 · Anti-CD38 Antibody Treating APS With ThrombocytopeniaUNKNOWN
PHASE2🇨🇳 China
NCT05644210 · Telitacicept Followed With Rituximab Therapy on APS Secondar…UNKNOWN
🇨🇳 China
NCT05020782 · The BeLimumab Antiphospholipid Syndrome Trial (BLAST)UNKNOWN
PHASE2, PHASE3🇮🇹 Itália
NCT05128760 · Impact of Antiphospholipid Antibodies on Thrombin Generation…UNKNOWN
🇫🇷 França
NCT05378516 · Placental Pathology and Inflammatory Factor Analysis of OAPSUNKNOWN
🇨🇳 China
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
4.783 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 4.783

#1

Magnetic Resonance Imaging-Negative Lupus Myelitis: A Narrative Review.

Annals of Indian Academy of Neurology2026 Mar 24

Magnetic resonance imaging (MRI)-negative lupus myelitis (MNLM) is a rare neurological manifestation of systemic lupus erythematosus (SLE). Diagnosing MNLM without prior systemic involvement remains challenging. This review aims to analyze all published cases and compare MNLM patients with (Group A) and without prior SLE diagnosis (Group B), emphasizing on demographic and clinical profiles, treatment, and outcomes. A PubMed literature review on MNLM was conducted. Demographic profile, clinical presentations, and management were analyzed. MNLM patients were categorized into Group A and B and compared using univariate and multivariate comparison methods, where a P value <0.05 was considered significant. In total, 41 cases were analyzed. The cohort was predominantly female (8:1 ratio, mean age 31.22 ± 11.91 years, range 15-59 years). Thoracic cord involvement was the most common (55%), with myelitis presenting as the first manifestation in 49% of patients. Clinical presentations were predominantly subacute (71%) with partial tract involvement in 63%. Group A demonstrated significantly higher cervical cord localization (P = 0.019) compared to Group B's thoracic involvement (P = 0.041). Antiphospholipid syndrome (APS) antibody-positive patients showed 3.2-fold higher odds for partial recovery (P = 0.16). Logistic regression analysis identified Anti Smith/ Ribonucleoprotein/ Ribosomal (Sm/RNP/Rib) antibodies as independent risk factors for poor complete recovery (odds ratio (OR) = 0.61), whereas cervical cord localization independently improved odds for complete recovery (OR = 3.2). MNLM presents with variable clinical manifestations suggesting selective tract involvement. Group A exhibits higher cervical involvement, while Group B shows predominantly thoracic involvement. APS antibodies favor partial recovery, cervical localization predicts complete recovery, and Sm/RNP/Rib antibodies are independent predictors of poor recovery outcomes.

#2

A Common Missense Variant, W335S, in β2-Glycoprotein I (APOH) is Associated with Increased Autoantibody Levels but Reduced Venous Thromboembolism Risk.

medRxiv : the preprint server for health sciences2026 Mar 05

Anti-β2-glycoprotein I (anti-β2GPI) antibodies are central to the pathogenesis of antiphospholipid syndrome (APS), an autoimmune disease characterized by a strong predisposition to venous thromboembolism (VTE). In this study, we conducted a multi-ancestry genome-wide association study (GWAS) of quantitative total anti-β2GPI levels in 5,969 participants enrolled in the Multi-Ethnic Study of Atherosclerosis (MESA) and identified a genome-wide significant association at the APOH locus. Paradoxically, genetically determined increases in anti-β2GPI levels at this locus were associated with lower VTE risk. Fine-mapping and functional genomics prioritized the missense variant rs1801690 (W335S) in β2GPI (apolipoprotein H, [APOH]) as the most likely causal variant. This variant has an allele frequency of 5-6% in European and East Asian ancestries but only 1% in African ancestries. Integrating prior experimental studies, molecular dynamics simulations and structure-based epitope prediction, we propose a dual-effect mechanism whereby W335S reduces thrombotic risk by disrupting phospholipid binding in Domain V, yet increases autoantibody production through conformational changes that enhance epitope exposure in Domains I and II. These findings mechanistically uncouple autoantibody formation from thrombotic risk in carriers of the W335S variant, and suggest that APOH genotype may represent a clinically relevant genetic biomarker with potential utility for thrombotic risk stratification in anti-β2GPI-positive individuals.

#3

Hyperbaric oxygen therapy for post-partum bell's palsy associate with anti-phospholipid syndrome: a case report, literature review, and mechanistic insights.

Frontiers in rehabilitation sciences2026

Bell's palsy, the most common cause of acute facial paralysis, can occur more frequently during pregnancy and postpartum due to physiological changes such as fluid retention, hormonal shifts, and immune modulation. Antiphospholipid syndrome (APS), an autoimmune disorder characterized by thrombosis and pregnancy related complications, further increases the risk of microvascular ischemia affecting cranial nerves. We report the case of a 37-year-old woman with longstanding APS who developed postpartum Bell's palsy unresponsive to corticosteroid therapy. Despite receiving 60 mg of prednisone, no clinical improvement was noted. Hyperbaric oxygen therapy (HBOT) was initiated, prescribed for 20 sessions at 2 absolute atmospheres, 5 days per week. Remarkable improvement was observed after the first session, with complete symptom resolution by the twelfth session. Additionally, anti-dsDNA antibodies, previously positive during pregnancy, became negative following HBOT. HBOT may represent a valuable adjunctive treatment for postpartum Bell's palsy in high-risk populations such as those with APS, offering combined benefits of enhanced oxygenation, inflammation control, and vascular repair. Further prospective studies are warranted to validate these findings and define standardized treatment protocols.

#4

Perioperative Management of Antithrombotic Therapy in Patients with Thrombotic Antiphospholipid Syndrome.

Blood advances2026 Mar 17

Patients with thrombotic antiphospholipid syndrome (APS) frequently require interruption of anticoagulation for invasive procedures, yet data to guide perioperative management remain limited. We conducted a single-center retrospective cohort study of adults with thrombotic APS who underwent planned periprocedural interruption of anticoagulation between 2016 and 2025. Primary outcomes were the 30-day risks of arterial thromboembolism (ATE), venous thromboembolism (VTE), and major bleeding; secondary outcomes included clinically relevant non-major bleeding (CRNMB), microvascular APS manifestations, and catastrophic APS (CAPS). Among 172 patients undergoing 282 interruptions, most (84.9%) received warfarin, and 25% were triple-positive (anti-cardiolipin, anti-β2-glycoprotein I, and lupus anticoagulant). Bridging with low-molecular-weight heparin (LMWH) was used in 84.7% of warfarin interruptions. Therapeutic-dose bridging was more frequently used in patients with triple-positive APS (OR 7.6; 95%CI 3.2-18.2) and in those with prior ATE (OR 3.4; 95%CI 1.5-7.8). The 30-day risk of ATE was 0.7% (95%CI 0.2-2.6). Major bleeding occurred in 0.7% (95%CI 0.2-2.6), with both events following high-bleed-risk procedures. One bleeding event was fatal, corresponding to a mortality risk of 0.4% (95%CI 0.1-2.0). CRNMB occurred in 3.2% (95%CI 1.7-6.0). A single case of probable CAPS occurred in a triple-positive patient receiving postoperative prophylactic LMWH. Guideline-directed perioperative anticoagulation management tailored to individual thrombotic and procedural bleeding risks appears feasible and safe. Our findings support individualized, risk-adapted perioperative anticoagulation management in APS.

#5

Are there disparities in cerebral sinus venous thrombosis between the Arab and Jewish populations in Israel - a multicenter cohort study?

Journal of the neurological sciences2026 Feb 27

Cerebral sinus venous thrombosis (CSVT) is a rare stroke subtype and data regarding the impact of ethnicity on its presentation and outcomes are limited. The Israeli CSVT cohort, which includes databases from six academic medical centers, was retrospectively studied. Demographics, clinical presentations, risk factors, radiological findings, and outcome parameters were compared between Jewish and Arab Israeli patients. The study included 554 patients with CSVT, of whom 71 (13%) were of Arab ethnicity and 483 (87%) were Jewish. Arab patients were younger (mean age 38.4 ± 15.8 vs. 42.8 ± 10.1 years, p = 0.027), and more frequently male (48% vs. 33%, p = 0.013). Rates of Behcet's disease (BD) were higher among Arabs patients (13% vs. 3%, p < 0.001), antiphospholipid syndrome (23% vs. 10%, p = 0.002) and any coagulopathy (48% vs. 35%, p = 0.04), but lower rates of hypertension (4% vs. 15%, p = 0.016), and use of oral contraceptives (9% vs. 26%, p = 0.002). Differences in clinical presentation included higher rates of headache (90% vs. 74%, p = 0.004) and vomiting (39% vs. 15%, p < 0.001) in the Arab patient group. Arab ethnicity was associated with lower rates of any recanalization (aOR 0.346 [0.172-0.695], p = 0.003), and complete recanalization (aOR 0.408 [0.209-0.795], p = 0.008). Despite these differences, rates of favorable outcomes, mortality, and CSVT recurrence were similar between the groups. The findings highlight notable ethnic variations in the risk factors and clinical manifestations of CSVT between Arab and Jewish populations living in the same physical surroundings. Understanding these ethnic differences is crucial for creating targeted prevention and treatment strategies that cater to the specific needs of these diverse groups.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC6.356 artigos no totalmostrando 193

2026

Nonbacterial Thrombotic Endocarditis and Mechanical Valve Thrombosis in a Patient with Antiphospholipid Syndrome.

CASE (Philadelphia, Pa.)
2026

Magnetic Resonance Imaging-Negative Lupus Myelitis: A Narrative Review.

Annals of Indian Academy of Neurology
2026

Do Patients with Antiphospholipid Syndrome Present with More Significant Venous Thromboembolic Clot Burden? A Retrospective Single-Center Study.

Hematology reports
2026

Genetic determinants of arterial thrombosis in primary antiphospholipid syndrome: a systematic review.

Frontiers in immunology
2026

Case Report: Differential diagnosis and clinical management of isolated prolonged activated partial thromboplastin time.

Frontiers in immunology
2026

RNA sequencing-derived gene co-expression and drug-gene interaction analysis reveal STAT1 as a potential therapeutic target in thrombotic antiphospholipid syndrome.

Frontiers in immunology
2026

A Common Missense Variant, W335S, in β2-Glycoprotein I (APOH) is Associated with Increased Autoantibody Levels but Reduced Venous Thromboembolism Risk.

medRxiv : the preprint server for health sciences
2026

Reversible Clozapine-Induced Antiphospholipid Syndrome.

The primary care companion for CNS disorders
2026

Hyperbaric oxygen therapy for post-partum bell's palsy associate with anti-phospholipid syndrome: a case report, literature review, and mechanistic insights.

Frontiers in rehabilitation sciences
2026

Monoclonal Gammopathies of Thrombotic and Hemorrhagic Significance: Mapping into a classification schema.

Journal of thrombosis and haemostasis : JTH
2026

Acute Myocardial Infarction Secondary to Triple Vessel Coronary Artery Disease in a 31-year-old Female with Systemic Lupus Erythematosus: Case Report and Review of Literature.

Acta medica Philippina
2026

Angiogenic imbalance and endothelial dysfunction in the placenta in antiphospholipid syndrome.

Autoimmunity reviews
2026

Perioperative Management of Antithrombotic Therapy in Patients with Thrombotic Antiphospholipid Syndrome.

Blood advances
2026

Acute Ischemic Stroke as the Initial Manifestation of Antiphospholipid Syndrome After SARS-CoV-2 Infection in a 17-Year-Old Patient.

Cureus
2026

Criterion and non-criteria antiphospholipid antibodies and acute coronary syndrome in the adult population under 55 years of age.

Medicina clinica
2026

Respond to "comments and opinions regarding "High antiphospholipid antibody titers and outcomes of pulmonary endarterectomy: a single-center retrospective observational cohort study" by Miard et al.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
2026

Effect of SARS-CoV-2 infection on the antiphospholipid antibodies and perinatal outcomes of pregnant patients with antiphospholipid syndrome.

Clinical rheumatology
2026

Management of patients with antiphospholipid antibodies or antiphospholipid syndrome during pregnancy.

Current opinion in rheumatology
2026

Hyposplenism in systemic lupus erythematosus: biological and radiological characteristics and its association with increased risk of infection.

RMD open
2026

[A case of antiphospholipid syndrome complicated with hyperhomocysteinemia presenting initially with central retinal vein occlusion in a young male].

[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
2026

Coexistent Antiphospholipid Syndrome with Polycythemia Vera in a 25-year-old Lady Presented with Splenic Vein Thrombosis.

The Journal of the Association of Physicians of India
2026

The role of clot waveform analysis and related parameters in the diagnosis and treatment of systemic lupus erythematosus.

Thrombosis research
2026

Autoimmunity beyond antibodies: alternative roles of beta-2-glycoprotein I in and out of antiphospholipid syndrome?

Current opinion in immunology
2026

Are there disparities in cerebral sinus venous thrombosis between the Arab and Jewish populations in Israel - a multicenter cohort study?

Journal of the neurological sciences
2026

Antiphospholipid antibodies and cardiovascular thrombosis.

Nature reviews. Cardiology
2026

Normalization of activated partial thromboplastin time and diluted Russell's viper venom time ratios can be safely omitted in the assessment of lupus anticoagulant.

Research and practice in thrombosis and haemostasis
2026

Impact of the 2023 ACR/EULAR antiphospholipid syndrome criteria in 1200 women with prior obstetric antiphospholipid syndrome.

European journal of obstetrics, gynecology, and reproductive biology
2026

Thrombotic recurrence after anticoagulation cessation in patients with antiphospholipid syndrome and antiphospholipid antibody negativization: a systematic review & meta-analysis.

Journal of thrombosis and haemostasis : JTH
2026

Reduction of regulatory B cells is associated with high-risk clinical stratification in antiphospholipid syndrome patients.

Immunologic research
2026

Hematologic disorders in pregnancy: the role of the complement system.

Expert review of hematology
2026

Blinatumomab in Combined Immune Thrombocytopenia and Antiphospholipid Syndrome.

The New England journal of medicine
2026

Catastrophic Antiphospholipid Syndrome: A Rare but Life-Threatening Thrombotic Storm-A Case Report and Literature Review.

Case reports in rheumatology
2026

Endothelial dysfunction in APS: advancing pathophysiological understanding to improve management.

Current opinion in immunology
2026

Mitral Valve Nonbacterial Thrombotic Endocarditis Associated With Antiphospholipid Syndrome in a Male Patient: A Comprehensive Case Report.

Case reports in medicine
2026

Criterion validity of the EULAR Antiphospholipid Syndrome Disease Activity Score (EAPSDAS).

Annals of the rheumatic diseases
2026

Myocardial infarction in a child with systemic lupus erythematosus.

BMJ case reports
2026

Obstetric antiphospholipid syndrome: Advances in pathogenesis.

Autoimmunity reviews
2026

Diffuse alveolar hemorrhage in antiphospholipid syndrome: Clinical presentation and prognosis.

Respiratory medicine
2026

Development of clinical manifestations in individuals positive for antiphospholipid antibodies according to the 2023 ACR/EULAR serological domains.

Seminars in arthritis and rheumatism
2026

Implementation of institutional thrombophilia guidelines and electronic medical record tools to reduce inpatient thrombophilia testing and costs.

Thrombosis research
2026

Revisiting antiphospholipid syndrome: A thrombo-inflammatory disorder beyond clotting.

Blood reviews
2026

Pulmonary Embolism as a Rare Complication of Anaplasmosis: A Case Report.

Cureus
2026

Comprehensive Review of Antiphospholipid Syndrome: Over Four Decades of Advances and Challenges.

Cells
2026

Prothrombotic fibrin clot phenotype in obstetric antiphospholipid syndrome: clinical implications and unanswered questions.

Polish archives of internal medicine
2026

Prothrombotic fibrin clot phenotype in obstetric antiphospholipid syndrome: clinical implications and unanswered questions. Authors' reply.

Polish archives of internal medicine
2026

Hydroxychloroquine therapy for women with both recurrent pregnancy loss and autoimmune disease: association with pregnancy outcomes and maternal-fetal complications.

Frontiers in immunology
2026

Validation of the 2023 American College of Rheumatology/European League Against Rheumatism antiphospholipid syndrome classification criteria in a Chinese systemic lupus erythematosus cohort.

Chinese medical journal
2026

Delayed diagnosis of recurrent embolic strokes from cardiac myxoma coexisting with antiphospholipid syndrome presenting as progressive cognitive decline.

BMJ case reports
2026

Monoclonal gammopathies of cutaneous significance: A nomenclature and pathophysiology-based classification.

Journal of the American Academy of Dermatology
2026

Quantifying Lupus Anticoagulant Interference in Intrinsic Coagulation Factor Activity Assays and Evaluating the Corrective Performance of the SCT-Based Method.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
2026

Expression levels of miR-146a-5p, miR-155-5p and the pro-inflammatory cytokine IL-8 in pregnant women with anti-phospholipid syndrome.

Lupus
2026

Fostamatinib treatment for patients with antiphospholipid syndrome and low platelet count: A case series.

British journal of haematology
2026

Multifocal Osteonecrosis in a Patient With Systemic Lupus Erythematosus and Antiphospholipid Syndrome Associated With Pyoderma Gangrenosum and Other Complications: A Case Report.

Case reports in medicine
2026

Multifactorial thrombotic risk in Evans syndrome: a case report and review of the literature.

Thrombosis journal
2026

Simvastatin Restores Uteroplacental Hemodynamics and Trophoblast Function in Obstetric Antiphospholipid Syndrome in a Placenta-on-a-Chip Model.

Advanced healthcare materials
2026

Coagulation parameter-based nomogram for the diagnosis of obstetric antiphospholipid syndrome and its subtypes.

Open life sciences
2025

Case Report: Telitacicept in the treatment of cSLE-APS: novel therapeutic perspectives on autoimmune thrombotic diseases in children.

Frontiers in immunology
2026

Histopathological placental findings in antiphospholipid antibody carriers with a fetal loss beyond 12 weeks of pregnancy.

Placenta
2026

aPLs seroconversion in antiphospholipid syndrome: from definition to clinical relevance.

Thrombosis research
2026

Anticoagulation, Recurrent Thrombosis and Major bleeding in antiphospholipid syndrome: UK multicentre observational study.

Blood advances
2026

Ischemic Stroke as the First Manifestation of Primary Antiphospholipid Syndrome in a Patient With a Recent Diagnosis of HIV: A Case Report.

Cureus
2026

Anti-phospholipid antibodies as a risk factor for renal injury in patients with systemic lupus erythematosus: a comprehensive analysis.

Frontiers in immunology
2026

Omadacycline - Associated Anticardiolipin Antibody Positivity and Hypercoagulable State: A Case Report and Review of Tetracycline - Induced Immune Dysregulation.

Infection and drug resistance
2026

Extracellular microvesicles from patients with antiphospholipid syndrome carry antigenic targets and promote endothelial cell activation in vitro.

Haematologica
2026

Preconception Hydroxychloroquine Therapy Restores Placental Function and Improves Pregnancy Outcomes in Obstetric Antiphospholipid Syndrome.

Antioxidants &amp; redox signaling
2026

[A clinical case of erythromelalgia in a patient comorbid with antiphospholipid syndrome].

Terapevticheskii arkhiv
2026

Catastrophic antiphospholipid syndrome in a 39-year-old woman.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne
2026

Increased placental villous macrophages in patients with antiphospholipid syndrome exacerbated during preterm pregnancy.

Placenta
2026

Lupus Anticoagulant and Complement C4 Consumption in Antiphospholipid Antibody Testing: Disentangling Inflammation From Autoimmunity.

International journal of laboratory hematology
2026

Intrapancreatic cysts as a diagnostic clue in antiphospholipid syndrome: a report of three cases.

Gastroenterology report
2026

Don't neglect the non-thrombotic manifestations of antiphospholipid syndrome in children - autoimmune hemolytic anemia and myocarditis: a case report and literature review.

Frontiers in immunology
2026

Implications of 2023 ACR/EULAR classification criteria for antiphospholipid syndrome and current diagnostic and therapeutic insights: A Delphi consensus.

The American journal of medicine
2026

In vivo targeting of open prothrombin with the monoclonal antibody POmAb results in anticoagulation without excessive bleeding.

Journal of thrombosis and haemostasis : JTH
2026

Translational immunothrombosis in autoimmune Heparin-Induced thrombocytopenia: targeting the FcγRIIa-Syk-BTK and complement pathways.

Clinical and experimental medicine
2026

Concomitant pulmonary embolism and severe thrombocytopenia associated with an APS-like autoimmune thrombophilic condition: a case report.

BMC pulmonary medicine
2026

Thrombin Generation Assays in Clinical Hemostasis: From Mechanistic Insights to Clinical Applications.

Seminars in thrombosis and hemostasis
2026

Integrating Anti-Phosphatidylserine/Prothrombin Antibodies Testing into Antiphospholipid Syndrome Diagnostics: A Multidomain, Expert Perception-Based Health Technology Assessment.

Diagnostics (Basel, Switzerland)
2026

Why low-dose aspirin persists in recurrent pregnancy loss without APS: cognitive bias and system design.

AJOG global reports
2026

Serum S100A8 as a potential biomarker for diagnosis of antiphospholipid syndrome and risk stratification among aPL carriers.

Lupus science &amp; medicine
2026

Inherited Thrombophilia as a Risk Factor for Persistent Left Ventricular Thrombus Following Acute Myocardial Infarction.

Thrombosis and haemostasis
2026

Complement involvement in antiphospholipid syndrome.

Immunology letters
2026

Animal models of antiphospholipid syndrome.

Frontiers in immunology
2026

Direct oral anticoagulants versus Vitamin K antagonist in kidney transplant recipients with atrial fibrillation: A study from a global federated research network.

European journal of internal medicine
2026

Uncommon clinical presentations and diagnostic difficulties of antiphospholipid syndrome associated with cryptococcal meningitis: A case study.

Medical mycology case reports
2026

Imaging features of catastrophic antiphospholipid syndrome : Massive saddle pulmonary embolism with subsequent complete resolution.

Radiology case reports
2025

Antiphospholipid Syndrome in Orthopaedic Foot and Ankle Surgery: A Propensity-Matched Analysis.

Foot &amp; ankle orthopaedics
2025

Co-Occurrence of Psoriasis/Psoriatic Arthritis and Antiphospholipid Syndrome: A Series of Nine Patients from a Single Centre and Literature Review.

Mediterranean journal of rheumatology
2026

The impact of anti-phosphatidylserine/prothrombin antibodies on pregnancy outcomes in patients with unexplained recurrent implantation failure: a retrospective cohort study.

Frontiers in immunology
2026

Recurrent venous thrombosis in an adolescent male with CBS mutation and persistent antiphospholipid antibody positivity: a case report.

Thrombosis journal
2026

Parallel improvement of chorea and antiphospholipid autoimmunity during combination therapy with hydroxychloroquine, belimumab, and glucocorticoids in systemic lupus erythematosus.

Modern rheumatology case reports
2026

Pulmonary Embolism and Myocardial Infarction With Non-obstructive Coronary Arteries in Immune Thrombocytopenia: Unmasking Underlying Antiphospholipid Syndrome.

Cureus
2026

Catastrophic antiphospholipid syndrome with eosinophilia mimicking hypereosinophilic syndromes with disseminated intravascular coagulation: a case report.

Journal of medical case reports
2026

Antiphosphatidylserine/prothrombin antibodies define a high-risk antiphospholipid syndrome profile associated with organ damage.

Clinical chemistry and laboratory medicine
2026

Caveolin-1 as a Marker of Endothelial Damage in Primary Antiphospholipid Syndrome Nephropathy.

Kidney medicine
2026

Anticoagulation Management of Patients with Antiphospholipid Syndrome Undergoing Cardiopulmonary Bypass in Cardiac Surgery: Challenges and Current Strategies.

Seminars in thrombosis and hemostasis
2026

Navigating clinical overlap: A case of polyarteritis nodosa in the setting of antiphospholipid syndrome.

Modern rheumatology case reports
2026

Pulmonary endarterectomy in antiphospholipid syndrome: a retrospective analysis from the Saudi pulmonary hypertension registry.

Frontiers in medicine
2026

Non-Huntington's disease chorea: an expanding universe with acquired causes.

Brain : a journal of neurology
2026

Exploring the prognostic significance of antiphospholipid antibody in acute myocardial infarction: insights from clinical study and mechanism.

Journal of thrombosis and haemostasis : JTH
2026

Molecular determinants of allosteric modulation of protein disulfide isomerase by small-molecule b'-ligands.

Redox biology
2025

Population developmental hazard of over-the-counter NSAIDs.

Folia medica Cracoviensia
2026

Catastrophic antiphospholipid syndrome: Clinical characteristics and outcomes in a non-caucasian population - A five-year experience from a single centre.

Lupus
2026

[Research progress on risk factors and risk prediction of cardiovascular diseases related to antiphospholipid syndrome].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]
2026

Activated Protein C Sensitivity Assessed with Thrombin Generation Assay in Antiphospholipid Syndrome Women: Results from Two French Cohorts.

Thrombosis and haemostasis
2026

Catastrophic Antiphospholipid Syndrome.

Seminars in thrombosis and hemostasis
2026

Ethnic differences in disease activity among patients with systemic lupus erythematosus in a universal public healthcare system.

Lupus
2025

A study of three-time-point dynamic changes in aPS/PT and standard aPL antibodies and their association with IVF pregnancy outcomes in APS-related recurrent pregnancy loss.

Frontiers in medicine
2025

Primary antiphospholipid syndrome presenting with unilateral renal infarction and C4d-positive cortical necrosis: a case report with a pooled analysis of 24 cases.

Frontiers in immunology
2025

Antigenic assessment for the β2-glycoprotein I/Platelet factor 4 complex in thrombotic patients with antiphospholipid syndrome.

Frontiers in immunology
2026

Pulmonary Embolism in Antiphospholipid Syndrome (APS)-Where Are We and Where Are We Going?

International journal of molecular sciences
2026

Distribution of Thrombophilia-Related Genetic Polymorphisms in Women with Reproductive Disorders.

Biomedicines
2026

Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT)-like Syndrome: A Case Report and Some Considerations on a Novel Diagnostic and Therapeutic Challenge.

Diagnostics (Basel, Switzerland)
2025

Thrombotic Storm: A Challenging Case of Catastrophic Antiphospholipid Syndrome.

Cureus
2026

Patient partnership model in rare and complex rheumatological conditions: research and beyond in European Reference Network ReCONNET.

The Lancet. Rheumatology
2026

DiGeorge Syndrome Complicated by Secondary Antiphospholipid Syndrome Presenting With Vascular Thrombosis.

Clinical case reports
2025

Terrible APS - a newly defined variant of severe APS.

Frontiers in immunology
2025

Primary antiphospholipid syndrome complicated by recurrent acute ST-elevation myocardial infarction: a case report.

Frontiers in cardiovascular medicine
2026

The diagnostic and prognostic values of non-criteria antiphospholipid antibodies in obstetric antiphospholipid syndrome.

BMC pregnancy and childbirth
2026

CD40-CD40L inhibition attenuates platelet-neutrophil interaction and neutrophil extracellular trap release in primary antiphospholipid syndrome.

Annals of the rheumatic diseases
2025

Risk factors for venous thromboembolism in Slovenian children and adolescents: a single center experience.

Frontiers in pediatrics
2025

A Case Report of Discoid Lupus Erythematosus Mimicking Skin Infection.

Reports (MDPI)
2025

Adrenal Crisis Masquerading as Sepsis in a Patient With Autoimmune Multimorbidity: A Diagnostic Challenge on the Acute Medical Ward.

Cureus
2026

Proton Pump Inhibitor-Induced Fundic Gland Polyps With Massive Bleeding Regressed on Alternative Histamine 2 Receptor Antagonist Therapy.

DEN open
2026

Outcomes of assisted reproductive technology in patients with immune-mediated rheumatic diseases: A systematic review and meta-analysis.

Journal of reproductive immunology
2026

Annexins and autoantibodies in autoimmune diseases - Insights into SLE, APS and RA: A review.

Biomolecules &amp; biomedicine
2026

Antiphospholipid Syndrome Mimicking Acute Exacerbation of Interstitial Pneumonia: A Case Report and Literature Review.

Respirology case reports
2025

Managing Pregnancy in the Presence of Rheumatic Heart Disease and Antiphospholipid Syndrome.

JACC. Case reports
2026

Functional imaging reveals cerebral microvascular dysfunction in primary antiphospholipid syndrome: Pathophysiologic insights and translational implications.

Journal of the neurological sciences
2026

Nicotinamide Riboside Mitigates Antiphospholipid Antibody-Induced Dysfunction in Human Trophoblast Cells.

American journal of reproductive immunology (New York, N.Y. : 1989)
2026

Surgical treatment of a giant aneurysm of the superior mesenteric artery in a patient with systemic lupus erythematosus.

Journal of surgical case reports
2026

Clinical features of non-criteria obstetric antiphospholipid syndrome: a retrospective cohort study on antibody-based risk classification and pregnancy outcomes.

BMC pregnancy and childbirth
2026

Prevalence, incidence proportion and independent predictors of thromboembolic events in adults with antiphospholipid syndrome: A systematic review with meta-analysis.

Phlebology
2025

Bilateral Adrenal Hemorrhage in Systemic Lupus Erythematosus and Antiphospholipid Syndrome: A Review of Mechanisms, Diagnosis, and Clinical Outcomes.

Cureus
2026

Complement activation and altered fibrin clot properties in obstetric antiphospholipid syndrome: impact on thromboembolism and pregnancy.

Clinical rheumatology
2026

[Chinese guidelines on clinical application of antiphospholipid antibodies (2026 edition)].

Zhonghua nei ke za zhi
2025

Successful Treatment of a Patient with Neuropsychiatric Lupus and Triple Positive Antiphospholipid Syndrome with Chronic Isolated Seizure: A Case Report.

Acta medica Philippina
2025

Complicated Pregnancy in a Patient with Distal Renal Tubular Acidosis, Systemic Lupus Erythematosus, and Antiphospholipid Syndrome: A Rare Case and Management Strategies.

Acta medica Indonesiana
2026

Navigating obstetric antiphospholipid syndrome: pathophysiology, diagnosis, and therapeutic advances.

Expert review of clinical immunology
2026

Elevated neutrophil-to-lymphocyte ratio and the incidence of autoimmune diseases: evidence from a large prospective cohort study.

Scientific reports
2026

Temporal trends in lupus pregnancy over four decades in a referral centre: pregnancy planning and hydroxychloroquine use are associated with improved outcomes.

Rheumatology advances in practice
2026

The regulatory roles of Beta-2 glycoprotein I (β2GPI) in thrombosis and hemostasis and abnormal disease conditions developed by autoantibodies against β2GPI.

Autoimmunity reviews
2026

The role of TLR2/MyD88/NF-κB pathway-mediated macrophage M1 polarization in recurrent spontaneous abortion associated with antiphospholipid syndrome.

Human cell
2025

Adrenal failure as an antiphospholipid syndrome manifestation: case-based review.

ARP rheumatology
2025

Cardiac sarcoidosis with a twist - active and fibrotic sarcoid with antiphospholipid positivity: A case report.

World journal of cardiology
2025

Role of antiphospholipid antibodies in kidney disease: Risk factors, immunopathogenesis, and diagnosis.

World journal of nephrology
2026

Antiphospholipid Antibodies in In vitro Fertilisation: Pathogenesis, Implantation Failure and Emerging Therapeutic Strategies.

The Nigerian postgraduate medical journal
2026

The Epigenetic Angle in the Precision Medicine Era for Blood Disorder Advancements.

Sub-cellular biochemistry
2025

Antiphospholipid antibodies induce endothelial procoagulant activity and release of extracellular vesicles independently of a second hit.

Frontiers in immunology
2025

Heterogeneity of antiphospholipid antibody profiles in a clinical cohort and association with distinct clinical features.

RMD open
2026

Antiphospholipid Syndrome Coexisting With Evans Syndrome and SCL-70 Antibody Positivity: A Case Report.

Clinical case reports
2026

Factors associated with venous and arterial thrombosis in patients with Systemic Lupus Erythematosus: A systematic review and meta-analysis.

Thrombosis research
2025

Postoperative Bilateral Renal Cortical Necrosis Secondary to Antiphospholipid Syndrome: A Case Report and Literature Review.

Canadian journal of kidney health and disease
2025

Fever of unknown origin, muscle weakness, and an adrenal nodule-the cat we chased like a hare: a case report.

Journal of medical case reports
2025

Hemorrhage or thrombosis? Adrenal involvements in a patient with antiphospholipid syndrome.

Rheumatology and immunology research
2025

Association between COVID-19 and New-Onset Autoimmune Diseases: Updated Systematic Review and Meta-Analysis of 97 Million Individuals.

Clinical reviews in allergy &amp; immunology
2025

Case Report: The case of atypical OAPS complicated by positive anti-SSA and anti-SSB antibodies.

Frontiers in immunology
2025

Maternal and neonatal outcomes in obstetric antiphospholipid syndrome: a retrospective case-control study.

Frontiers in medicine
2025

Recurrent ischaemic strokes as a first presentation of Libman-Sacks endocarditis with an atypically massive mitral vegetation resulting in severe valvular regurgitation: a case report.

European heart journal. Case reports
2026

Exploring the association between preeclampsia and antiphospholipid antibodies. A prospective study.

Lupus
2025

Massive Pulmonary Embolism in the Postpartum Period as the First Manifestation of Antiphospholipid Syndrome: A Case Report.

Cureus
2025

Whole transcriptome analysis and preliminary construction of ceRNA networks in obstetric antiphospholipid syndrome.

Frontiers in immunology
2025

Brain perfusion scintigraphy with [99mTc]Tc-HMPAO in patients with autoimmune diseases.

Nuclear medicine review. Central &amp; Eastern Europe
2025

Nationwide Temporal Trends in Adverse Pregnancy Outcomes and Treatments in Systemic Lupus Erythematosus Pregnancy Over Two Decades in Sweden.

Arthritis &amp; rheumatology (Hoboken, N.J.)
2025

Balancing Bleeding and Thrombosis: A Rare Case of Hereditary Hemorrhagic Telangiectasia With Antiphospholipid Syndrome.

Cureus
2026

New ACR/EULAR 2023 classification criteria for antiphospholipid syndrome, what should a gynaecologist know in 2025.

Journal of gynecology obstetrics and human reproduction
2026

The role of interferon-mediated suppression of monocyte immunothrombosis in infection susceptibility in systemic lupus erythematosus.

Clinical and experimental immunology
2026

Epidemiological perspectives on SLE and APS in MENA: Burden, barriers, and a path toward improved outcomes.

Lupus
2025

Libman-Sacks endocarditis of the mitral valve as a first presentation of systemic lupus erythematosus.

Journal of surgical case reports
2025

Fibrin clot properties as the missing link between obstetric and thrombotic antiphospholipid syndrome.

Polish archives of internal medicine
2026

Genetic and epigenetic insights into systemic lupus erythematosus: linking long non-coding RNA growth arrest-specific transcript 5 and interferon signature.

Journal of rheumatic diseases
2025

Atypical Manifestation of Primary Antiphospholipid Syndrome: Conservative Management of Celiac Trunk Thrombosis Case Report and Literature Review.

Clinical case reports
2025

Prothrombotic fibrin clot properties are associated with lower live births rate in women with obstetric antiphospholipid syndrome: a cohort study.

Rheumatology international
2026

[Analysis of follow-up and prognosis in pediatric rheumatic diseases associated with pulmonary embolism].

Zhonghua er ke za zhi = Chinese journal of pediatrics
2025

Autoimmune Adrenalitis in Systemic Lupus Erythematosus: Identifying a Rare Endocrine Complication.

Cureus
2025

[Clinic behavior and therapeutic status of patients with antiphospholipid syndrome].

Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
2025

Molecular Stratification of Antiphospholipid Syndrome Through Integrative Analysis of the Whole-Blood RNA Transcriptome.

Arthritis &amp; rheumatology (Hoboken, N.J.)
2025

Pathophysiology of Primary Budd-Chiari Syndrome: A Narrative Review.

Cureus
2026

Diffuse alveolar haemorrhage in antiphospholipid syndrome: a French series of 26 patients.

Rheumatology (Oxford, England)
2026

Loss of antiphospholipid antibody positivity decreases the risk of recurrent thrombosis in thrombotic antiphospholipid syndrome.

Rheumatology (Oxford, England)
2025

Antiphospholipid syndrome presents with aortic thrombosis and central venous catheter-related thrombosis: a case report.

Thrombosis journal
2025

Tubulointerstitial nephritis and uveitis syndrome: an unexpected diagnosis.

BMJ case reports
2025

Immune-mediated mechanisms and maternal-fetal interface dysfunction in obstetric antiphospholipid syndrome.

Frontiers in immunology
2025

Incidental finding of antiphospholipid antibody syndrome in a patient with Cor Pulmonale: A case report.

JPMA. The Journal of the Pakistan Medical Association
2025

Acute myocardial infarction and antiphospholipid syndrome: an updated systematic review and meta-analysis.

Annals of medicine and surgery (2012)
2026

Severe Aortic Stenosis and Dual Valve Vegetations: An Uncommon Presentation of Primary Antiphospholipid Syndrome.

JACC. Case reports
2025

Osteonecrosis of Femoral Head with Antiphospholipid Syndrome and Acquired Subclinical Hemophilia A.

Clinical laboratory
2025

Different phenotypes of severe flares in patients with systemic lupus erythematosus: results of a clustering analysis in a monocentric cohort.

Frontiers in immunology
2025

Artificial intelligence in antiphospholipid syndrome: toward individualized risk prediction.

Research and practice in thrombosis and haemostasis
2025

Mitral Valve Repair for Mitral Regurgitation Associated with Antiphospholipid Syndrome: A Case Report.

Surgical case reports
2025

Hydroxychloroquine does not affect endotheliopathy or coagulopathy biomarkers in COVID-19: longitudinal results from the DisCoVeRy randomized trial.

Angiogenesis
2025

Severe Hemoperitoneum From a Ruptured Ovarian Cyst in a Patient with Antiphospholipid Syndrome and Antithrombin III Deficiency: A Case Report.

The American journal of case reports
2026

Challenges in Revascularization in Patients With Systemic Lupus Erythematosus.

JACC. Case reports
2025

Obstetric antiphospholipid syndrome: evolving classification and implications for clinical practice and research.

Reumatologia
Ver todos os 6.356 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Síndrome antifosfolipídico.

É de uma associação que acompanha esta doença? Fale com a gente →

Vai consultar um especialista? Confirme o registro dele no conselho.
Conselhos e sociedades

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Perguntas frequentes

O que as famílias mais perguntam sobre esta doença — cada resposta com a fonte de onde saiu

Respostas geradas por IA a partir das fontes citadas

Trata-se de uma condição autoimune crônica para a qual não há dados de cura definitiva catalogados nos registros médicos oficiais. O manejo concentra-se em reduzir a ocorrência de novos eventos trombóticos e complicações obstétricas.

Referências

Fontes citadas no texto, publicações do grafo e bases de dados usadas neste verbete

10 publicações do grafo RarasNet (PubMed) · 4 bases de dados. Títulos, periódicos e PMIDs vêm direto da fonte, sem intermediação de IA.

  1. ORPHA:80
    Orphanet
  2. GARD:5824
    GARD (NIH)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Citar este verbete

Raras. (s.d.). Síndrome antifosfolipídico. Em Raras — Enciclopédia de Doenças Raras do Brasil. https://raras.org/doenca/sindrome-antifosfolipidico

Formato APA. Conteúdo sob CC BY 4.0 — reuso livre com atribuição.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Compêndio · Raras BR

Síndrome antifosfolipídico

ORPHA:80 · MONDO:8000010
CID-10
D68.6 · Outros defeitos da coagulação
CID-11
Ensaios
51 ativos
MedGen
UMLS
C0085278
EuropePMC
Papers 10a

📋 Origem dos dados

Esta página agrega dados de fontes públicas e oficiais. Dados sobre cobertura no SUS (PCDT, CEAF) são verificados ativamente por agente proativo (ver badge no infobox). Demais dados têm atribuição de fonte + data da última sincronização — clique para abrir o original.

Doença rara (ontologia)
fonte: Orphanet
Identificador unificado
fonte: MONDO
Indexação biomédica
fonte: MeSH (NLM)
Rara